Compare RILYP & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RILYP | HUMAW |
|---|---|---|
| Founded | 1973 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2014 | 2020 |
| Metric | RILYP | HUMAW |
|---|---|---|
| Price | $12.69 | $0.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 49.3K |
| Earning Date | 01-01-0001 | 03-21-2025 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ 138.49 | 79.37 |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $967,599,000.00 | $2,038,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.02 | ★ N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $3.25 | $0.00 |
| 52 Week High | $17.52 | $0.40 |
| Indicator | RILYP | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 32.00 |
| Support Level | $12.43 | N/A |
| Resistance Level | $13.75 | $0.01 |
| Average True Range (ATR) | 0.36 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 40.36 | 0.00 |
BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services, telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across various business lines. The Group has seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Capital Markets segment, which provides investment banking and institutional brokerage services, offers loans, trades in equity securities, and maintains an investment portfolio of public and private equities and debt securities. Geographically, the Group derives maximum revenue from its business in North America.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.